Affiliation:
1. Harvard University
2. Global Health and Health Policy Harvard University
3. MGH Weight Center Massachusetts General Hospital Nutrition Obesity Research Center at Harvard, Harvard Medical School
Abstract
Policy Points
Health policymakers have insufficiently addressed care for people with obesity (body mass index ≥ 30 kg/m2) in the United States. Current federal policies targeting obesity medications reflect this unfortunate reality.
We argue for a novel policy framework to increase access to effective obesity therapeutics and care, recognizing that, though prevention is critical, the epidemic proportions of obesity in the United States warrant immediate interventions to augment care.
Reducing barriers to and improving the quality of existing anti‐obesity medications, intensive behavioral therapy, weight management nutrition and dietary counseling, and bariatric surgery are critical. Moreover, to ensure continuity of care and patient–clinician trust, combating physician and broader weight stigma must represent a central component of any viable obesity care agenda.
Funder
National Institute of Diabetes and Digestive and Kidney Diseases
Reference61 articles.
1. Prescription Drug Benefits 42 USC §1395w‐102(2018).
2. Definitions 42 USC §1395x(2020).
3. US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity
4. Treat and Reduce Obesity Act of 2021 HR 1577 117th Cong (2021‐2022). March 4 2021. Accessed March 6 2023.https://www.congress.gov/bill/117th‐congress/house‐bill/1577